Prophylactic Pegfilgrastim Versus On-Demand Filgrastim During Docetaxel and Cyclophosphamide Chemotherapy in Early-Stage Breast Cancer: A Retrospective Analysis

The administration of pegfilgrastim significantly reduced the risk of FN development, with acceptable adverse events. The chemotherapy RDI of patients who received prophylactic pegfilgrastim was significantly higher than that of those who were administered conventional filgrastim at the physician's discretion. In the present study, we verified the clinical efficacy of pegfilgrastim in patients receiving TC chemotherapy. The prophylactic use of pegfilgrastim is considered to be essential for carrying TC chemotherapy safely.